Outcomes of aortic stenosis in patients with cardiac amyloidosis: A systematic review and meta-analysis

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiovascular Revascularization Medicine Pub Date : 2025-04-01 DOI:10.1016/j.carrev.2025.02.005
Soban Ahmad , Muhammad Junaid Ahsan , Morgan Newlun , Mitchell Sand , Anan Abu Rmilah , Amman Yousaf , Muhammad Asim Shabbir , Shahbaz A. Malik , Andrew M. Goldsweig
{"title":"Outcomes of aortic stenosis in patients with cardiac amyloidosis: A systematic review and meta-analysis","authors":"Soban Ahmad ,&nbsp;Muhammad Junaid Ahsan ,&nbsp;Morgan Newlun ,&nbsp;Mitchell Sand ,&nbsp;Anan Abu Rmilah ,&nbsp;Amman Yousaf ,&nbsp;Muhammad Asim Shabbir ,&nbsp;Shahbaz A. Malik ,&nbsp;Andrew M. Goldsweig","doi":"10.1016/j.carrev.2025.02.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Cardiac amyloidosis (CA) results from the deposition of abnormally folded protein fibrils, leading to restrictive cardiomyopathy, valvular heart disease, and arrhythmias. Up to 15 % of patients with severe aortic stenosis (AS) have concomitant CA (AS-CA). We conducted this systematic review and meta-analysis to compare medical management, transcatheter aortic valve replacement (TAVR), and surgical AVR (SAVR) in AS-CA.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted for relevant studies from inception through January 20, 2024. Studies exploring outcomes in adult AS patients with and without CA receiving medical therapy, TAVR, or SAVR were included in this analysis.</div></div><div><h3>Results</h3><div>Fifteen studies including 253,334 patients (AS-CA 6704; AS alone 246,630) were identified. AS-CA patients had significantly higher all-cause mortality (RR = 2.60, 95 % CI 1.48–4.57, <em>P</em> = 0.0009) compared to AS alone. Among patients with AS-CA, TAVR was associated with lower all-cause mortality compared to both medical therapy (RR = 0.50, 95 % CI 0.29–0.89, <em>P</em> = 0.02) and SAVR (RR = 0.41, 95 % CI 0.22–0.78, <em>P</em> = 0.007). AS-CA patients undergoing TAVR were more likely to have paradoxical low-flow, low-gradient AS (RR = 1.56, 95 % CI 1.15–2.12, <em>P</em> = 0.04) at baseline and had a higher risk of post-TAVR acute kidney injury (RR = 1.95, 95 % CI 1.35–2.80, <em>P</em> = 0.0003) compared to patients undergoing TAVR for AS alone. There were similar risks of other post-TAVR complications, including major bleeding, vascular complications, stroke, and new pacemaker implantation between AS-CA and AS alone.</div></div><div><h3>Conclusion</h3><div>CA is associated with a higher mortality in patients with severe AS. In patients with concomitant AS and CA, TAVR is safe and associated with better survival than medical therapy or SAVR.</div></div><div><h3>Social media abstract</h3><div>#Meta-Analysis: Cardiac amyloidosis is associated with increased mortality in severe AS. #TAVR is safe in amyloidosis &amp; improves survival more than medical therapy or SAVR.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"73 ","pages":"Pages 98-106"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Revascularization Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1553838925000478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Cardiac amyloidosis (CA) results from the deposition of abnormally folded protein fibrils, leading to restrictive cardiomyopathy, valvular heart disease, and arrhythmias. Up to 15 % of patients with severe aortic stenosis (AS) have concomitant CA (AS-CA). We conducted this systematic review and meta-analysis to compare medical management, transcatheter aortic valve replacement (TAVR), and surgical AVR (SAVR) in AS-CA.

Methods

A comprehensive literature search was conducted for relevant studies from inception through January 20, 2024. Studies exploring outcomes in adult AS patients with and without CA receiving medical therapy, TAVR, or SAVR were included in this analysis.

Results

Fifteen studies including 253,334 patients (AS-CA 6704; AS alone 246,630) were identified. AS-CA patients had significantly higher all-cause mortality (RR = 2.60, 95 % CI 1.48–4.57, P = 0.0009) compared to AS alone. Among patients with AS-CA, TAVR was associated with lower all-cause mortality compared to both medical therapy (RR = 0.50, 95 % CI 0.29–0.89, P = 0.02) and SAVR (RR = 0.41, 95 % CI 0.22–0.78, P = 0.007). AS-CA patients undergoing TAVR were more likely to have paradoxical low-flow, low-gradient AS (RR = 1.56, 95 % CI 1.15–2.12, P = 0.04) at baseline and had a higher risk of post-TAVR acute kidney injury (RR = 1.95, 95 % CI 1.35–2.80, P = 0.0003) compared to patients undergoing TAVR for AS alone. There were similar risks of other post-TAVR complications, including major bleeding, vascular complications, stroke, and new pacemaker implantation between AS-CA and AS alone.

Conclusion

CA is associated with a higher mortality in patients with severe AS. In patients with concomitant AS and CA, TAVR is safe and associated with better survival than medical therapy or SAVR.

Social media abstract

#Meta-Analysis: Cardiac amyloidosis is associated with increased mortality in severe AS. #TAVR is safe in amyloidosis & improves survival more than medical therapy or SAVR.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
心脏淀粉样变性患者主动脉瓣狭窄的结局:系统回顾和荟萃分析。
背景:心脏淀粉样变性(CA)是由异常折叠的蛋白原纤维沉积引起的,可导致限制性心肌病、瓣膜性心脏病和心律失常。高达15%的严重主动脉狭窄(AS)患者伴有CA (AS-CA)。我们对AS-CA的内科治疗、经导管主动脉瓣置换术(TAVR)和外科主动脉瓣置换术(SAVR)进行了系统回顾和荟萃分析。方法:全面检索自成立至2024年01月20日的相关研究。本分析纳入了探讨合并和不合并CA的成人AS患者接受药物治疗、TAVR或SAVR的结果的研究。结果:15项研究,包括253,334例患者(AS-CA 6704;仅AS就有246,630例。AS- ca患者的全因死亡率明显高于单纯AS患者(RR = 2.60, 95% CI 1.48-4.57, P = 0.0009)。在AS-CA患者中,与药物治疗(RR = 0.50, 95% CI 0.29-0.89, P = 0.02)和SAVR (RR = 0.41, 95% CI 0.22-0.78, P = 0.007)相比,TAVR与较低的全因死亡率相关。与单纯接受TAVR的AS患者相比,接受TAVR的AS- ca患者在基线时更有可能出现矛盾的低流量、低梯度AS (RR = 1.56, 95% CI 1.15-2.12, P = 0.04),并且TAVR后急性肾损伤的风险更高(RR = 1.95, 95% CI 1.35-2.80, P = 0.0003)。其他tavr后并发症的风险相似,包括大出血、血管并发症、卒中和AS- ca与单独AS之间的新起搏器植入。结论:CA与严重AS患者较高的死亡率相关。在合并AS和CA的患者中,TAVR是安全的,与药物治疗或SAVR相比,生存率更高。摘要:荟萃分析:心脏淀粉样变性与严重AS患者死亡率增加相关。TAVR治疗淀粉样变性是安全的,比药物治疗或SAVR更能提高生存率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardiovascular Revascularization Medicine
Cardiovascular Revascularization Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.30
自引率
5.90%
发文量
687
审稿时长
36 days
期刊介绍: Cardiovascular Revascularization Medicine (CRM) is an international and multidisciplinary journal that publishes original laboratory and clinical investigations related to revascularization therapies in cardiovascular medicine. Cardiovascular Revascularization Medicine publishes articles related to preclinical work and molecular interventions, including angiogenesis, cell therapy, pharmacological interventions, restenosis management, and prevention, including experiments conducted in human subjects, in laboratory animals, and in vitro. Specific areas of interest include percutaneous angioplasty in coronary and peripheral arteries, intervention in structural heart disease, cardiovascular surgery, etc.
期刊最新文献
Editorial: Epicardial-only left atrial appendage closure: Insights from seven years of first-in-human experience. Indications, contraindications, and usefulness of acetylcholine testing. Impact of thinner strut design on current generation drug-eluting stent in all-comers. The fluoroscopic IVUS X-mark IT (FIX-IT) technique: A reproducible, image-guided approach to ostial stent deployment. From paradoxical to preventable: The hole story.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1